Availabio gives brand teams access to evidence-graded bioavailability parameters, CYP interaction data, and IVIVE-informed PK estimates — so formulation discussions are grounded in something more specific than label claims.
Outputs are model-derived estimates. Not for regulatory submission or clinical label claims.
Before writing a product brief or committing to a delivery format, brand teams often encounter questions that existing literature reviews don't fully resolve.
A product team is evaluating whether a phospholipid-complexed curcumin warrants the cost premium over a standard 95% extract. The published studies vary in design and the absolute absorption numbers differ significantly across sources. The team wants to know how the parameters compare — and how strong the evidence is for each estimate before writing the brief.
Bioavailability parameters for both forms — Cmax ratios, Tmax ranges, AUC estimates — drawn from curated sources with grade assignments per parameter.
Each parameter is graded A–D based on the quality of the source data — not the efficacy of the compound. Grade B means the estimate is drawn from reasonably good sources with some conflicting data; it doesn't mean the ingredient is less effective.
Availabio does not validate product claims, confirm label compliance, or substitute for a full regulatory review. The data informs formulation discussions — it does not replace them.
Every parameter in Availabio carries a grade. Grades describe how strong the underlying source data is — not how effective a compound will be in a product.
Multiple high-quality sources with consistent findings. Parameter estimate is reliable for formulation planning purposes.
Reasonably strong primary sources. Some variation between studies. Use with directional confidence; note the range.
Fewer sources, smaller studies, or heavy reliance on in vitro data extrapolated to human estimates. Treat as hypothesis-generating data.
Very limited published data. Estimate is based on structural analogy or computational modeling only. Useful for early scoping, not for brief commitments.
Important: A Grade C or D compound is not necessarily less effective. The grade reflects the depth of available PK data for that specific parameter — not a clinical judgment of the compound's value in a formulation.
Availabio feeds into different parts of the product and commercial process.
Compare delivery formats, assess absorption differences between ingredient variants, and flag interaction assumptions early in the development cycle.
Access curated PK parameters with source references. Use IVIVE-informed simulation estimates to pressure-test formulation hypotheses before in-house testing.
Before a product brief is written, check whether the evidence tier supports the positioning direction. Distinguish strongly evidenced parameters from estimated ones.
Pull structured PK parameter data directly into your own tools via the Availabio API. Batch compound queries, integrate with product databases, or power internal dashboards.
All plans include the core compound database and evidence grades. Higher tiers add API access, team seats, and direct design partner involvement.
A walkthrough takes 30 minutes. We cover your compound library, the evidence grades that apply, and how the API or platform maps to your workflow.
Educational and formulation intelligence use only. PK simulation outputs are model-derived estimates informed by IVIVE methodology. Outputs are not clinical advice, not legal advice, and not intended for regulatory submission. Availabio does not validate product efficacy claims, label statements, or regulatory filings.